Incyte Corp | INCY - Sales Revenues

YTE reported $926.7M in Sales Revenues for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Sales Change
Amgen AMGN:US USD 6.84B 187M
Biogen BIIB:US USD 2.54B 35.5M
Bluebird Bio BLUE:US USD 71K 1.45M
Bristol Myers Squibb BMY:US USD 11.41B 188M
Clovis Oncology CLVS:US USD 30.66M 1.48M
Eli Lilly And LLY:US USD 7.3B 360.2M
Exelixis EXEL:US USD 423.92M 12.18M
Gilead Sciences GILD:US USD 7.39B 347M
Merk MRK:US USD 13.83B 1.13B
Neurocrine Biosciences NBIX:US USD 412M 24.1M
Newlink Genetics NLNK:US USD 512K 15K
Novartis NOVN:VX USD 13B 159M
Novartis NVS:US USD 13B 159M
Pfizer PFE:US USD 24.29B 1.65B
Regeneron Pharmaceuticals REGN:US USD 3.41B 478.2M
Seattle Genetics SGEN:US USD 528.15M 17.85M
Ultragenyx Pharmaceutical RARE:US USD 103.35M 12.64M
Vertex Pharmaceuticals VRTX:US USD 2.3B 31.6M
YTE INCY:US USD 926.7M 103.4M